Mono Pharmacare Ltd
Incorporated in 1994, Mono Pharmacare Limited is engaged in the business of marketing and distribution of pharmaceutical products[1]
- Market Cap ₹ 61.6 Cr.
- Current Price ₹ 34.8
- High / Low ₹ 75.0 / 31.8
- Stock P/E 21.4
- Book Value ₹ 17.2
- Dividend Yield 0.00 %
- ROCE 12.3 %
- ROE 11.8 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 151 to 90.0 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.1.70 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|
| 13.92 | 70.72 | 80.50 | |
| 13.05 | 68.19 | 77.43 | |
| Operating Profit | 0.87 | 2.53 | 3.07 |
| OPM % | 6.25% | 3.58% | 3.81% |
| 0.20 | 1.69 | 1.70 | |
| Interest | 0.38 | 1.28 | 1.23 |
| Depreciation | 0.02 | 0.08 | 0.07 |
| Profit before tax | 0.67 | 2.86 | 3.47 |
| Tax % | 19.40% | 14.69% | |
| 0.54 | 2.44 | 2.87 | |
| EPS in Rs | 0.44 | 1.38 | 1.63 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 42% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|
| Equity Capital | 12.37 | 17.67 | 17.67 |
| Reserves | 1.03 | 10.44 | 12.73 |
| 12.51 | 13.27 | 17.89 | |
| 3.15 | 4.02 | 11.75 | |
| Total Liabilities | 29.06 | 45.40 | 60.04 |
| 0.19 | 0.14 | 0.20 | |
| CWIP | 0.00 | 0.00 | 0.02 |
| Investments | 1.97 | 3.59 | 0.00 |
| 26.90 | 41.67 | 59.82 | |
| Total Assets | 29.06 | 45.40 | 60.04 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | |
|---|---|---|
| -13.49 | -10.32 | |
| -2.18 | -1.66 | |
| 15.90 | 12.00 | |
| Net Cash Flow | 0.23 | 0.02 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Debtor Days | 211.87 | 90.01 |
| Inventory Days | 466.39 | 118.95 |
| Days Payable | 64.21 | 16.55 |
| Cash Conversion Cycle | 614.04 | 192.41 |
| Working Capital Days | 614.89 | 193.03 |
| ROCE % | 12.33% |
Documents
Announcements
-
Updates
22 November 2024 - Mono Pharmacare Limited has informed regarding 'Reciept of Consent letter and Brief profile of Ms. Drashti Rohit Chande for appointment as Additional Independent Director of …
-
Outcome of Board Meeting
14 November 2024 - Mono Pharmacare Limited has informed regarding Board meeting held on November 14, 2024.
-
Financial Result Updates
14 November 2024 - Mono Pharmacare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2024.
-
Board Meeting Intimation
6 November 2024 - MONO PHARMACARE LIMITED has informed about Board Meeting to be held on 14-Nov-2024 to consider and approve the Half Yearly Unaudited Financial results of the …
-
Updates
21 October 2024 - Mono Pharmacare Limited has informed regarding 'Non applicability of Corporate Governance for the Quarter ended September 30, 2024'.
Business segment
A) Marketing of Pharmaceutical Products[1]
Co. outsources manufacturing of most of its products and has 19 third-party manufacturers and sells all these products under its own Brand name - “DLS Export”.
Product Portfolio[1] Health Care products, Antibiotic medicines, Cough Cold Allergic medicines, Antifungal medicines, Nutraceutical medicines, Analgesic and antipyretic medicines, Antacid and antiemetics medicines, Cardiac - Diabetic medicines, and cosmocare products.